The Microdose Psychedelics Capital Conference virtual event will commence on Thursday, March 24, 2022, 1:30 EST, and investors, family officers, budding entrepreneurs, psychedelic researchers, medical & science specialists and health professionals are invited to attend. The agenda of the conference will include discussions, keynotes, and insights from world-class speakers, top companies, as well as the latest IPOs, all addressing the potential and scope of investments in the psychedelic sector.
The conference will explore specific opportunities in the psychedelic investment sector, along with discussions on the latest innovations in drug development, pertinent laws and regulations, and business trends. This virtual event is a part of the bi-monthly investor series that explores the immense scope of psychedelic investment and connects new businesses to the leading capital industries and investors of the psychedelic arena.
The conference is organized by Microdose, a premier organization focused on creating, offering and distributing the most compelling content on the finance, industry news, science, and the latest breakthroughs and events of the psychedelic industry. This is a robust platform offering exposure to professionals, companies, and individuals about the events of the psychedelic industry.
This PsyCap event will focus on topics like corporate social responsibility (“CSR”), environmental, social and governance (“ESG”), market consolidation, and explore the possibilities of a potential investment.
The Doing Good segment of Psychedelic Capital features presentations from a non-profit organization from the industry. At this event, the PsyCap Doing Good presentation is hosted by the World Happiness Foundation.
The introduction of the Microdose event will be given by:
- Patrick Moher, President, Microdose Psycheledics Insights, is a young entrepreneur dedicated to creating unique business opportunities across the social and economic spectrum for budding industries and individuals.
- Richard Skaife, Chair, Microdose, The Conscious Fund, a veteran in mental health technology and investment
The virtual conference will feature corporate presentations from industry veterans like Clearmind Medicine and Med Plant Science, and offers a unique opportunity for growing companies to connect with peers and industry leaders. Investors can gain access to phenomenal pre-IPO investments opportunities across the psychedelic sector.
The Microdose Group’s first investment opportunity is with HIVE Bio which has partnered with Med Plant Science Ltd to enable safe and legal access of psychedelics medicine to patients. Med Plant Science Ltd, is a biotech company focused on developing psychedelic products, from plants and mushrooms.
To learn more, please visit https://ibn.fm/t47sm.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.